Trials / Completed
CompletedNCT00480246
A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- BioLineRx, Ltd. · Industry
- Sex
- Male
- Age
- 21 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
This is a single dose, open-label, 2-panel (Parts A and B) PET study investigating the degree of occupancy of dopamine 2 receptors (D2\_RO) in the human brain after single oral doses of BL-1020 or Perphenazine (Trilafon®, hereafter called Perphenazine) in healthy male subjects. In Part A the D2\_RO is investigated for the study compound BL-1020 and in Part B the D2\_RO of BL-1020 is compared to the D2\_RO of Perphenazine, a reference compound.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL 1020 | |
| DRUG | Perphenazine |
Timeline
- Start date
- 2007-05-01
- First posted
- 2007-05-30
- Last updated
- 2009-07-21
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00480246. Inclusion in this directory is not an endorsement.